Dyslipidemia among newly diagnosed hypertensives: Pattern and clinical correlates

Journal of the National Medical Association

Volumn 102, Issue 5, 2010, Pages 403-407

  Akintunde, Adeseye A ^a,b   Ayodele, E Olugbenga ^a   Akinwusi, Olayinka P ^c   Opadijo, George O ^a  

^a Ladoke Akintola University   (Nigeria)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c NONE

Author keywords

Cholesterol; Hypertension; Lipids; Prevalence

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NIGERIA; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TEACHING HOSPITAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77953172860     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30575-7     Document Type: Article

References (33)

1. Castelli WP, Garrisson WP, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipid cholesterol levels: The Framingham study. JAMA. 1986;256:2835-2838.
2. Yano K, Reed DM, McGee DL. Ten year incidence of coronary heart disease in the Honolulu Heart program: Relationship to biologic and lifestyle characteristics. Am J Epidemiol. 1984;119:653-666.
3. Wilson PW, Anderson KM, Castelli WP. Twelve year incidence of coronary heart disease in middle aged adults during the era of hypertensive therapy: The Framingham offspring study. Am J Med. 1991;90:11-16.
4. Velagaletti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence: The Framingham Heart study. Circulation. 2009;120:2345-2351.
5. Schmieder RE, Ruilope LM. Blood Pressure control in patients with comorbidities. J Clin Hypertens (Greenwich). 2008;10:624-631.
6. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-822.
7. Zanchetti A. Hyperlipidaemia in the hypertensive patient. Am J Med. 1994;96(suppl 6A):3S-8S.
8. Ko M, Kim M, Nam J. Assessing risk factors of coronary heart disease and its prediction among Korean adults; the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol. 2006;110:184-190.
9. Feldstein CA. Statins as antihypertensives. Recent Pat Cardovasc Drug. 2008;3:92-97.
10. Kesteloot H, Oviasu VO, Obasohan AO et al. Serum lipid and apolipoprotein levels in a Nigerian population sample. Atherosclerosis. 1989;78:33-38.
11. Desai PP, Bunker CH, Ukoli FA, KambohMI. Genetic variation in the apolipoprotein D gene among African Blacks and its significance in lipid metabolism. Atherosclerosis. 2002;163:329-338.
12. Akpa MR, Agomouh D, Alasia DD. Lipid profile of healthy adult Nigerians in Port Harcourt, Nigeria. Nig J Med. 2006;15:137-140.
13. Opadijo OG, Akande AA, Jimoh AK. Prevalence of coronary heart disease risk factors in Nigerians with systemic hypertension. Afr J Med Med Sci. 2004;33:121-125.
14. Ukoh VA, Oforofuo IA.Plasma lipid profiles in Nigerians with normal blood pressure, hypertension and other acquired cardiac conditions. East Afr Med J. 2007;84:264-270.
15. Chobanian AV, Bakris GL, Black HR,et al. and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure JNC VII. Hypertens. 2003;12:1206-1252.
16. Lepira FB, M'Buyamba-Kabangu JR, Kayembe KP, Nseka MN. Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension. Cardiovasc J S Afr. 2005;16:249-255.
17. Oghagbon EK, Okesina AB. Pattern of some risk factors for cardiovascular disease in untreated Nigerian hypertensive patients. West Afr J Med. 2006;25:190-194.
18. Verdecchia P, Reboldi G, Angeli F, et al. Prognostic value of lipoprotein fractions in essential hypertension. Blood Press. 2004;13:295-303.
19. Lepira FB, Kayembe PK, M'buyamba-Kabangu JR, Nseka MN. Clinical correlates of left ventricular hypertrophy in black patients with arterial hypertension. Cardiovasc J S Afr. 2006;17:7-11.
20. Opadijo OG, Omotoso AB, Akande AA. Relation of electrocardiographic left ventricular hypertrophy to blood pressure, body mass index, serum lipids and blood sugar levels in adult Nigerians. Afr J Med Med Sci. 2003;32:395-399.
21. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-822.
22. Cordero A, Andres E, Ordonez B, et al. Usefulness of triglycerides-to- high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am J Cardiol. 2009;104:1393-1397.
23. Gupta R, Guphta S, Agrawal A, Kaul V, Gaur K, Gupta VP. Secular trends in cholesterol lipoproteins and triglycerides and prevalence of dyslipidaemia in an urban Indian population. Lipids Health Dis. 2008;7:40.
24. Odenigbo CU, Oguejiofor OC, Odenigbo UM, Ibeh CC, Ajaero CN, Odike MA. Prevalence of dyslipidaemia in apparently healthy professionals in Asaba, South-South Nigeria. Niger J Clin Prac. 2008;11:330-335.
25. NIH Consensus Conference. Triglycerides, high density lipoprotein and coronary heart disease.NIH Consensus Development Panel on Triglycerides, high density lipoprotein and coronary heart disease. JAMA. 1993;269:505-510.
26. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart study. Can J Cardiol. 1988;4(suppl A):5A-10A.
27. Ingelsson E, Schaeffer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776-785.
28. Gotto AM Jr. Lipid risk factors and the regression of atherosclerosis. Am J Cardiol. 1995;76:3A-7A.
29. Sacks FM, Rudel LL, Conner A, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res. 2009;50:894-907.
30. Hanefeld M, Hora C, Schulze J, Rothe G, Barthel U,Haller H. Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study. Atherosclerosis. 1984;53:47-58.
31. National Cholesterol Education Programme: Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002;106:3143-3421.
32. Watson KE, Ansell BJ, Watson AD, Fonarow GC. HDL functions as a target of lipid modifying therapy. Rev Cardiovasc Med. 2007;8:1-8.
33. Chapmann MJ, Assmann G, Michart JC, Sheperd J, Sirtori C. European Consensus Panel on HDL-C. Raising HDL lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20:1253-1268.